Resumen
Purpose: This study aimed to develop objective diagnostic criteria for early onset Marfan syndrome (eoMFS) to facilitate early diagnosis and timely interventions. Methods: On the basis of an extensive literature review and the responses from a survey distributed among providers with expertise in the diagnosis and management of eoMFS, we developed an age-based, diagnostic scoring system encompassing 10 features common to eoMFS (9 clinical + 1 laboratory) and divided them into cardiac, systemic, and FBN1 (on the basis of the location of the pathogenic FBN1 variant) scores. Results: In total, 77 individuals with eoMFS (13 newly reported) and 49 individuals diagnosed with classical Marfan syndrome during early childhood were used to validate the criteria. Median cardiac (8 vs 0, P <.001), systemic (11 vs 3, P <.001), FBN1 (5 vs 0, P <.001), and total (23 vs 4, P <.001) scores were significantly higher in individuals with eoMFS than in those without. A proposed clinical score (cardiac + systemic) cutoff of ≥14 points showed excellent sensitivity (100%), specificity (92%), and reliability (correctly classified = 94%). Conclusion: Distinct from classical Marfan syndrome in phenotype and morbidity, eoMFS can be diagnosed clinically using an objective scoring system encompassing the typical physical features and cardiac disease manifestations. Although genetic testing can be suggestive of eoMFS, genetic testing alone is insufficient for diagnosis.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 1503-1511 |
| Número de páginas | 9 |
| Publicación | Genetics in Medicine |
| Volumen | 24 |
| N.º | 7 |
| DOI | |
| Estado | Published - jul 2022 |
Nota bibliográfica
Publisher Copyright:© 2022 American College of Medical Genetics and Genomics
Financiación
The authors would like to thank the providers who responded to the initial survey. Support for REDCap was made possible through the University of Arkansas for Medical Sciences Translational Research Institute (NCATS/NIH UL1 RR029884). Conceptualization: Y.A.Z. S.A.M. A.B. R.T.C.; Formal Analysis: Y.A.Z. A.B. C.A.A. B.S.C.; Investigation: Y.A.Z. S.A.M. A.B. A.J.K. K.E.Y. E.M.M. K.N.W. R.T.C.; Resources: Y.A.Z. C.A.A. B.S.C.; Writing-original draft: Y.A.Z. R.T.C.; Writing-review and editing: Y.A.Z. S.A.M. C.A.A. K.E.Y. E.M.M. K.N.W. R.T.C. Approval for the review and reporting of these cases was given by the Institutional Review Board of the University of Arkansas for Medical Sciences. Data from the survey distributed to the providers were anonymized. Written informed consent was obtained from individual ID#62 for the scientific use of photo documentation.
| Financiadores | Número del financiador |
|---|---|
| National Institutes of Health (NIH) | UL1 RR029884 |
| National Center for Advancing Translational Sciences (NCATS) | |
| University of Arkansas for Medical Sciences | |
| Translational Research Institute, University of Arkansas for Medical Sciences |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Genetics(clinical)
Huella
Profundice en los temas de investigación de 'A clinical scoring system for early onset (neonatal) Marfan syndrome'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver